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Background: The phagocytic enzyme myeloperoxidase (MPO) acts as a front-line defender against microorgan-
isms. However, increasedMPO levels have been found to be associatedwith complex and calciﬁed atherosclerot-
ic lesions and incident cardiovascular disease. Therefore, this study aimed to investigate a predictive role of MPO,
a biomarker of inﬂammation and oxidative stress, for total and cardiovascular mortality in patients referred to
coronary angiography.
Methods and results:MPOplasma concentrations alongwith eightMPOpolymorphismswere determined in 3036
participants of the Ludwigshafen Risk and Cardiovascular Health study (median follow-up 7.75 years). MPO con-
centrations were positively associated with age, diabetes, smoking, markers of systemic inﬂammation (interleu-
kin-6, ﬁbrinogen, C-reactive protein, serum amyloid A) and vascular damage (vascular cellular adhesion
molecule-1 and intercellular adhesionmolecule-1) but negatively associated with HDL-cholesterol and apolipo-
protein A-I. After adjustment for cardiovascular risk factors MPO concentrations in the highest versus the lowest
quartile were associated with a 1.34-fold risk (95% CI: 1.09–1.67) for total mortality. In the adjusted model the
hazard ratio for cardiovascular mortality in the highest MPO quartile was 1.42 (95% CI: 1.07–1.88). Five MPO
polymorphisms were positively associated with MPO concentrations but not with mortality. Using Mendelian
randomization, we did not obtain evidence for a causal association of MPO with either total or cardiovascular
mortality.
Conclusions:MPOconcentrations but not genetic variants at theMPO locus are independently associatedwith risk
for total and cardiovascular mortality in coronary artery disease patients.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Myeloperoxidase (MPO), a member of the heme peroxidase family,
is abundantly expressed in neutrophils and monocytes at sites of
inﬂammation [1]. Under physiological conditions MPO reacts with
halides, thiocyanate and nitrite and the corresponding MPO-derived
oxidation products play an important role in phagocyte's antimicrobial
armoury by killing invading pathogens thereby contributing to hostCenter for Molecular Medicine,
gasse 21, A-8010 Graz, Austria.
.
land Ltd. This is an open access articldefence [1,2]. However, persistent activation of MPO results in elevated
levels of reactive chlorine species andMPO-derived oxidants have been
linked with neurodegenerative disorders, carcinogenesis, lung disease
and respiratory damage, rheumatoid arthritis, kidney damage and ath-
erosclerosis [1,3–6].
An association between MPO levels and the risk of coronary artery
disease (CAD) has ﬁrst been reported in 2001 [7]. Since then, numerous
studies have addressed the role of MPO as a circulating inﬂammatory
marker in chronic heart failure [8,9], acute coronary syndrome (ACS)
[10–12], and CAD [13]. Besides various prospective and cross-sectional
studies examining the relationship between MPO and the presence of
atherosclerosis or the risk of future CAD, evidence cameup that a certain
MPO polymorphism in the promoter region (−463G/A) might bee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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assumed to determine MPO levels and to be associated with plasma
levels of common risk factors for atherosclerosis and even the progres-
sion of atherosclerosis but also to predict a likely risk for cancer [15].
Several studies have investigated the predictive value of MPO for
short-term recurrence of cardiovascular events, while only limited
studies have concentrated onMPO as amarker for long-term cardiovas-
cular risk. Therefore, the present study aimed at investigating (i)
whether MPO concentration is an independent predictor of total and
cardiovascular mortality in patients undergoing coronary angiography,
(ii) the relationship between genetic polymorphisms of MPO and
plasma MPO levels, and (iii) the association of these MPO poly-
morphisms with total and/or cardiovascular mortality.
2. Materials and methods
2.1. Study design and participants
The Ludwigshafen Risk and Cardiovascular Health (LURIC) study includes 3316 con-
secutive white Caucasian patients hospitalized for coronary angiography between June
1997 and May 2001 [16]. The Ethics Review Committee at the “Landesärztekammer
Rheinland-Pfalz” (Mainz, Germany) approved the study. Informed written consent was
obtained from each participant. Clinical indications for angiography were chest pain or
non-invasive tests consistent with myocardial ischaemia. With the exception of ACSs,
the patients had to present in a stable clinical condition without major concomitant
non-cardiovascular disease.
CAD has been deﬁned angiographically using the maximum luminal narrowing
estimated by visual analysis. We deﬁned clinically relevant CAD using as a criterion the
occurrence of at least one stenosis of ≥20% as pre-speciﬁed in the study protocol [16] in
at least one of 15 coronary arterial segments according to Austen et al. [17]. Individuals
with stenoses of less than 20% were considered not having CAD. Of the 3036 individuals
645 (21.3%) had no angiographic CAD. Out of 2391 CAD patients 479 (20%) had their
diagnosis made seven days or less before the day of blood sampling. Alternatively we
deﬁned CAD as at least one stenosis of ≥50% narrowing (see: Supplementary Tables IIIA
and IIIB). The severity of CAD was assessed using the Friesinger score [18].
Diabetesmellituswas diagnosedwhen (i) plasma glucosewas N1.25 g/L in the fasting
state or N2.00 g/L 2 h after the oral glucose load, respectively, or (ii) when HbA1c was
≥6.5% or (iii) when individuals were receiving oral anti-diabetics or insulin. Hypertension
was diagnosed (i) if the systolic and/or diastolic blood pressure exceeded 140 and/or
90 mm Hg or (ii) if individuals were on anti-hypertensive medication: angiotensin-
converting enzyme (ACE)-inhibitors, angiotensin-II type-1 (AT1) receptor antagonists,
beta-blockers, calcium channel blockers, and diuretics. The estimated glomerularﬁltration
rate (eGFR) was calculated using the chronic kidney disease epidemiologic collaboration
(CKD-EPI) formula [19]. Left ventricular function had been graded semi-quantitatively
by contrast ventriculography into normal or slightly, moderately, or severely impaired
[16].
The primary and secondary outcomemeasures were total and cardiovascular mortal-
ity, respectively. Information on vital status was obtained from local person registries. For
deceased patients, information on the cause of deathwas extracted fromdeath certiﬁcates
obtained from local health authorities. No patients were lost to follow-up. Of the 3036
subjects included in this examination, 708 deaths (23.3%) had occurred during a median
observation time of 7.75 years. Cardiovascular death included the following categories:
sudden death, fatal myocardial infarction (MI), death due to congestive heart failure,
death immediately after intervention to treat CAD, fatal stroke, and other causes of
death due to CAD. Cause of death of 23 participants was unknown. These individuals
were included in the calculation of total mortality but not in the analysis of cardiovascular
mortality.
2.2. Laboratory measurements
Fasting blood samples were drawn by venipuncture before coronary angiography
according to a standardized protocol. Centrifugation (2600 g, 4 °C, 15min)was performed
within 15–20 min of blood collection. Whole blood, plasma, and DNA were stored at
−80 °C. The standard laboratory methods used were described elsewhere [16].
Lipoproteins were separated by a combined ultracentrifugation–precipitation method.
C-reactive protein (CRP, N high sensitivity CRP) and serum amyloid A (SAA, N Latex
SAA) were measured by immunonephelometry (Behring Nephelometer II, Dade Behring,
Marburg, Germany). Fibrinogen was determined using the Clauss method (STA ﬁbrino-
gen, Roche, Mannheim, Germany). PlasmaMPO levels were determined using a commer-
cially available sandwich ELISA assay with two polyclonal anti-MPO antibodies
(Immundiagnostik AG, Bensheim, Germany). Intra-assay and inter-assay variations
were 3.9% and 8.3%, respectively; the limit of detection was 1.6 ng/mL. ELISA assays
(R&D Systems Inc., Minneapolis, MN) were used to measure plasma levels of
interleukin-6 (IL-6), vascular cellular adhesionmolecule-1 (VCAM-1) and intercellular ad-
hesion molecule-1 (ICAM-1). N-terminal pro-B-type natriuretic peptide (NT-proBNP) was
measured by an electrochemoluminescence enzyme immunoassay (ECLIA, Roche
Diagnostics, Mannheim, Germany). During the recruitment period troponin T (TnT) wasdetermined by ECLIA (Roche Diagnostics, Mannheim, Germany) using a cut-off at 0.1 μg/L;
post hoc, we used a fourth generation ECLIA from Roche Diagnostics with high sensitivity.
2.3. Analysis of MPO polymorphisms
Genomic DNA was isolated from whole blood by standard methods [16]. MPO
genotypes were determined by 5′ exonuclease assays (TaqMan). Applied Biosystems
‘Assay-by-Design’ custom service (Applied Biosystems, Vienna, Austria) was used for the
design and manufacture of primer and probe sets. Sequences of primers and probes are
presented in Table I (Supplementary). Endpoint ﬂuorescence data were exported into
Excel format and analysed as scatter plot. Sampleswere analysed in batches, each contain-
ing 95 samples and a negative control (water instead of DNA).
2.4. Statistical analysis
Normal distribution was assessed using QQ-Plot and Shapiro–Wilk test. Parameters
not normally distributed were transformed logarithmically for statistical analyses. We
established quartiles of continuous variables according to the values in individuals with-
out angiographic CAD. Associations of categorical and continuous variables were analysed
by logistic regression and univariate analysis of variance (ANOVA), respectively, with co-
variables. We studied the effects of gender, age, CAD, cardiovascular risk factors, and in-
ﬂammatory markers on MPO using ANOVA models in which we included those factors
not under examination as co-variables. To assess the predictive value of models with
and without MPO for cardiovascular and total mortality we used reclassiﬁcation analysis
including receiver operating characteristic (ROC) curves, net reclassiﬁcation improve-
ment, and integrated discrimination index. The association of MPO polymorphisms and
MPO plasma concentrations was analysed using ANOVA models assuming a co-
dominant (homozygosity for the major MPO allele, heterozygosity and homozygosity
for theminor allele) or a dominant (homozygosity for themajor MPO allele and presence
of at least one minor allele) effect of the minor allele. We undertook genetic instrumental
variable analysis using a combined variable of two single nucleotide polymorphisms
(SNPs) (c.−822CNA, rs2243827; g.5237GNA, rs11575868; category 0 [no minor allele],
category 1 [heterozygosity or homozygosity for rs2243827 or rs11575868], category 2
[heterozygosity or homozygosity for rs2243827 and rs11575868]). Cox proportional
hazard models were used to examine the association of the instrumental variable with
total and/or cardiovascular mortality. To examine the relationship of MPO levels on total
and cardiovascular mortality, hazard ratios (HRs) and 95% conﬁdence intervals (CIs)
were calculated using Cox proportional hazard models according to quartiles of MPO.
Multivariable adjustment was carried out for age, sex, intake of lipid lowering drugs,
CAD status, and risk factors as indicated. All statistical tests are 2-sided; P b 0.05 is
considered signiﬁcant. We used the SPSS 17.0 statistical package (SPSS Inc., Chicago, IL),
STATA 11 (StataCorp LP 4905 Lakeway Drive, College Station, Texas 77845-4512, USA),
and the R version 2.15.2 (R Foundation for Statistical Computing).
3. Results
3.1. Study participants
Compared with non-CAD patients, patients with angiographically
conﬁrmed CAD were signiﬁcantly older and more likely to be male
(Table 1). Current or past smoking, type 2 diabetes, hypertension, car-
diovascular medication, impaired left ventricular function, and cerebro-
vascular and peripheral artery disease were more prevalent in the CAD
group. Fifty-three percent of the CAD patients had a history of MI. The
CAD patients had signiﬁcantly higher systolic blood pressure, fasting
glucose, triglycerides, and signiﬁcantly lower HDL-cholesterol (HDL-C)
and eGFR compared to patients without CAD. Low-density lipoprotein-
cholesterol (LDL-C) was slightly lower in CAD patients than in patients
without CAD, even after adjustment for the use of lipid-lowering drugs.
Body mass index, diastolic blood pressure, and MPO concentration
were similar in both groups (Table 1).
3.2. Association of MPO with cardiovascular risk factors and CAD status
We examined the effect of gender, age, angiographic CAD, and risk
factors on MPO levels in a general linear model where we included
those factors not under examination as co-variables (Table 2).MPO con-
centrations were independent of gender but signiﬁcantly increased
with age. The concentration of MPO was not associated with the sever-
ity of atherosclerosis (Friesinger coronary score, Table 2) [18]. Signiﬁ-
cantly higher MPO concentrations were found in patients with
diabetes mellitus (P = 0.010) but not in patients with the metabolic
syndrome without diabetes mellitus. Current smokers had signiﬁcantly
Table 1
Clinical and biochemical characteristics of study participants at baseline.
All individuals
(n = 3036)
Without CAD
(n = 645)
With CAD
(n = 2391)
Pa
Age (years) means ± SD 63 ± 11 58 ± 12 64 ± 10 b0.001
Male sex (%) 70 52 75 b0.001b
Body mass index (kg/m2) means ± SD 27 ± 4 27 ± 4 28 ± 4 0.335
Diabetes mellitus (%) 40 27 44 b0.001
Systemic hypertension (%) 73 63 76 0.001
Smoking
Never(%) 36 52 32
Past (%) 44 30 48 b0.001
Current (%) 20 18 20 b0.001
Unstable CAD, TnT- (%) 19 – 24 –
Unstable CAD, NSTEMI or STEMI (%) 12 – 16 –
Previous myocardial infarction (%) 42 – 53 –
Peripheral vascular disease (%) 10 2 12 b0.001
Cerebrovascular disease (%) 8 5 9 0.023
Systolic blood pressure (mm Hg) means ± SD 141 ± 24 136 ± 22 143 ± 24 0.005c
Diastolic blood pressure (mm Hg) means ± SD 81 ± 11 80 ± 11 81 ± 12 0.510c
Semiquantitative left ventricular function
Normal (%) 71 79 68
Slightly impaired (%) 11 6 12 b0.001
Moderately impaired (%) 12 9 13 0.043
Severely impaired (%) 7 6 7 0.669
Lipid-lowering drugs (%) 51 18 57 b0.001
Beta-blockers, % 64 69 45 b0.001
ACE inhibitors, % 54 58 36 b0.001
AT1 receptor antagonists, % 4.6 4.3 4.7 0.809
Calcium channel blockers, % 16 13 17 0.501
Diuretics, % 29 26 30 0.852
Aspirin and/or other antiplatelet agents, % 72 43 80 b0.001
Fasting blood glucose (mg/L) means ± SD 113 ± 36 105 ± 28 116 ± 37 b0.001
eGFR, CKD-EPI (mL/min/1.73 m2) means ± SD 84.6 ± 19.4 89.3 ± 17.3 83.3 ± 19.7 0.030
LDL-C (mg/dL) means ± SD 116 ± 34 119 ± 31 115 ± 34 0.005d
HDL-C (mg/dL) means ± SD 39 ± 11 43 ± 12 38 ± 10 b0.001d
Triglycerides (mg/dL) 147 133 150 b0.001d, e
median (25th and 75th percentile) (110–200) (97–194) (113–202)
NT-proBNP (ng/L) 297 158 336 b0.001e
median (25th and 75th percentile) (108–874) (71–498) (128–964)
Myeloperoxidase (ng/mL) 30.3 30.3 30.3 0.731e
median (25th and 75th percentile) (20.8–47.1) (20.7–45.4) (20.8–47.7)
ACE (angiotensin converting enzyme).
AT1 (angiotensin 1).
CKD-EPI (Chronic Kidney Disease Epidemiologic Collaboration).
eGFR (estimated Glomerular Filtration Rate).
NT-proBNP (N-terminal pro-B-type natriuretic peptide).
NSTEMI (non-ST elevation MI).
STEMI (ST elevation MI).
TNT- (Troponin-T not increased).
a Analysis of variance (ANOVA) or logistic regression, respectively, adjusted for age and gender; comparison between individuals with and without CAD.
b Logistic regression, adjusted for age only.
c Adjusted for use of beta blockers, ACE inhibitors, AT1 receptor antagonists, calcium channel blockers, diuretics and lipid-lowering agents.
d Adjusted for use of lipid-lowering agents.
e ANOVA of logarithmically transformed values.
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decreased with increasing quartiles of HDL-C and apolipoprotein A-I,
with 13.3% (P= 0.010) and 12.0% (P= 0.048) lower mean MPO con-
centrations, respectively, in the fourth compared to the ﬁrst quartile.
Hypertension, body mass index, LDL-C, apolipoprotein B and triglycer-
ides were not signiﬁcantly associated with MPO levels. However,
patients on lipid lowering drug therapy (primarily statins) had on aver-
age 8.1% (P= 0.018) lowerMPO concentrations compared to untreated
subjects. Multiple linear regression with forward selection of the inde-
pendent variables listed in Table 2 selected ﬁve signiﬁcant predictors
of MPO concentration in the order of HDL-C N age N use of lipid-
lowering drugs N smoking status N diabetes mellitus.
We were interested to see if MPO concentrations were increased in
ACS. We stratiﬁed our study population into persons without CAD,stable CAD, unstable CAD, those presentingwith acute non-ST elevation
myocardial infarction (NSTEMI) or STEMI (less than 7 days after onset of
symptoms), STEMI between 7 and 15 days after onset of symptoms or
STEMI more than 15 days ago. As expected TnT (Supplementary Fig. I)
was markedly elevated in acute NSTEMI or STEMI, while MPO levels
were only slightly increased (Supplementary Fig. II).
3.3. Association of MPO with inﬂammatory markers
We then examined whether MPO concentrations were associated
withmarkers of acute/chronic inﬂammation. Levels of the inﬂammatory
marker IL-6, as well as levels of major acute-phase reactants (CRP, SAA,
ﬁbrinogen) increased in parallel to MPO (Fig. 1). This relationship was
independent of conventional coronary risk factors. Furthermore, MPO
Table 2
Association of MPO with cardiovascular risk factors and coronary artery disease.
MPO (ng/mL)a Difference (%)b Pc
Gender
Men 34.3 (33.0–35.7)
Women 32.3 (30.4–34.4) −5.7 0.132
Age (years)
b60 31.9 (30.1–33.9)
60–70 34.1 (32.3–36.0) +6.8 0.112
N70 35.4 (33.1–37.5) +11.0 0.017
Lipid-lowering drugs
No 35.1 (33.5–36.8)
Yes 32.3 (30.0–33.9) −8.1 0.018
Coronary artery disease
None 33.5 (31.0–36.2)
Stable CAD 33.8 (32.2–35.5) +1.0 0.837
Unstable CAD (Troponin T-) 33.6 (31.2–36.2) +0.3 0.969
Unstable CAD (Troponin T+) 33.5 (30.5–36.9) +0.1 0.992
Friesinger score
1st quartile (0–2) 32.4 (29.5–35.5)
2nd quartile (3–5) 34.6 (32.3–37.1) +6.9 0.241
3rd quartile (6–8) 33.4 (31.4–35.4) +3.1 0.617
4th quartile (9–15) 34.3 (31.9–36.8) +6.0 0.380
Left ventricular function
Normal 33.0 (31.7–34.4)
Slightly impaired 31.6 (28.4–35.1) −4.4 0.441
Moderately impaired 36.7 (33.3–40.5) +11.2 0.050
Severely impaired 39,2 (34.3–45.1) +19.0 0.017
Body mass index (kg/m2)
b26 or 273 34.1 (32.5–35.8)
N26 or 273 33.2 (31.8–34.8) −2.6 0.448
Metabolic syndrome/diabetes
None 31.9 (29.9–34.1)
Metabolic syndrome 32.6 (30.5–34.7) +2.0 0.699
Diabetes mellitus 36.0 (34.1–37.9) +12.7 0.010
Hypertension
No 33.5 (31.4–35.8)
Yes 33.7 (32.4–35.0) +0.5 0.898
Smoking
Never 32.8 (31.0–34.7)
Former 33.0 (31.4–34.7) +0.6 0.874
Current 37.2 (34.3–40.2) +13.3 0.015
eGFR (mL/min/1.73 m2)
≥90 32.3 (30.7–34.0)
60–89 33.6 (31.9–35.3) +4.0 0.319
30–59 38.5 (34.6–42.8) +14.6 b0.001
b30 34.4 (25.4–46.5) +6.5 0.689
NT-proBNP (ng/L)
1st quartile (b109) 30.9 (28.8–33.1)
2nd quartile (109–297) 33.1 (31.0–35.4) +7.3 0.144
3rd quartile (298–874) 33.1 (31.0–35.3) +7.1 0.163
4th quartile (N874) 37.8 (35.3–40.4) +22.3 b0.001
LDL cholesterol (mg/dL)
1st quartile (b101) 33.6 (31.7–35.6)
2nd quartile (101–119) 33.7 (31.6–36.1) +0.3 0.936
3rd quartile (120–141) 33.6 (31.4–36.0) +0.1 0.978
4th quartile (≥142) 33.7 (31.4–36.2) +0.2 0.975
HDL cholesterol (mg/dL)
1st quartile (b36) 35.5 (32.6–37.3)
2nd quartile (36–41) 33.2 (30.9–35.8) −6.3 0.191
3rd quartile (42–49) 33.0 (30.8–35.3) −7.0 0.103
4th quartile (≥50) 30.8 (28.1–33.6) −13.3 0.010
Apolipoprotein B (mg/dL)
1st quartile (b87) 33.6 (31.3–36.0)
2nd quartile (87–102) 33.0 (31.0–35.3) −1.6 0.744
3rd quartile (103–119) 33.2 (31.2–35.4) −1.1 0.830
4th quartile (N119) 34.9 (32.6–37.3) +3.9 0.467
Apolipoprotein A-I (mg/dL)
1st quartile (b123) 32.5 (28.1–37.6)
2nd quartile (123–137) 32.1 (27.9–36.9) −1.3 0.895
3rd quartile (138–157) 30.6 (26.5–35.4) −5.8 0.224
4th quartile (N157) 28.6 (24.8–33.0) −12.0 0.048
Triglycerides (mg/dL)
1st quartile (b98) 33.3 (29.4–37.9)
2nd quartile (99–132) 31.7 (29.4–34.3) −4.9 0.408
3rd quartile (133–194) 34.5 (32.6–36.6) +3.6 0.640
4th quartile (≥195) 34.7 (31.0–38.8) +4.1 0.720
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and ICAM-1, accepted markers of vascular damage.
3.4. Association of MPO polymorphisms with MPO plasma concentration
Next, we investigated the association of SNPs in the MPO gene [20]
with plasma MPO concentrations. The genotype distributions did not
differ signiﬁcantly from Hardy–Weinberg equilibrium. The minor allele
frequencies of the MPO SNPs ranged from 0.03 to 0.21 (Table 3A).
Assuming a dominant model, statistically signiﬁcant associations
with MPO levels were found for ﬁve SNPs. Three polymorphisms
(c.−822CNA, c.−765TNC, c.−653GNA [previously termed−463G/A])
are located in the 5′ region and may alter MPO expression. For these
SNPs the presence of at least one minor allele was associated with an
increase of MPO concentrations by 13.3, 10.0, and 10.0%, respectively.
Homozygosity of the minor allele in these SNPs did not further increase
MPO concentration (co-dominant model, Table 3B). The c.2149TNC
SNP (Ile717Val) was associated with an increase of MPO levels by
18.9% (Table 3A).
We constructed an instrumental variable based on genotypes from
two SNPs that have shown to be related with MPO plasma concentra-
tion (c.−822CNA (rs2243827) and g.5237GNA (rs11575868)). MPO
concentrations were signiﬁcantly different between genotypes with
higher concentration in the category 1 (Supplementary Table II)
compared to the categories 0 (no minor allele) and 2 (two minor
alleles). Thus, we ﬁtted the effect by a regression model that pools
categories 0 and 2. The mean difference between two genotype catego-
ries (0/2 versus 1)was 26.2 ng/mL. The variance of theMPO concentra-
tion explained by the instrumental variable was 0.43% (R-square).
3.5. MPO and mortality from all causes
Among the 3036 individuals studied, 708 deaths (23.3%) occurred
during a median follow-up of 7.75 years. Compared with individuals
in the lowest MPO quartile, the unadjusted HRs for death in the second
to the fourth MPO quartile were 1.28 (95% CI: 1.02–1.60, P = 0.033),
1.27 (95% CI: 1.01–1.60, P = 0.038), and 1.76 (95% CI: 1.42–2.17, P
b 0.001), respectively (Table 4 [Model 1], Fig. 2). Inclusion of age and
gender as co-variables only slightly altered these estimates (Table 4
[Model 2]). Although HRs decreased after additional adjustment for
the CAD status at presentation (no CAD, stable CAD, or unstable CAD)
and established cardiovascular risk factors, MPO retained its prognostic
importance in the fourth quartile (Table 4 [Model 3]).
Among the 2391 subjects with angiographic CAD, 627 participants
(26.2%) died during follow-up. In this subgroup, HRs for death were
similar to those obtained in the entire study population (Table 4
[Models 1–3], Fig. 2). Similar results were obtained in a subgroup of
patients with CAD deﬁned ≥50% of stenosis (Supplementary
Table IIIA). In patients without CAD (n = 645, 81 deaths), MPO levels
were not signiﬁcantly associated with total mortality (Table 4 [Models
2–3]). Considering the subgroup of individuals without CAD or with
stable CAD (n= 2083, 486 deaths), HRs were slightly higher compared
to the entire study population (Supplementary Table IIIA).
3.6. MPO and cardiovascular mortality
As death certiﬁcateswere not available from23patients, the analysis
for cardiovascular mortality included 3013 individuals in total. AmongNotes to Table:
a Estimated marginal means and 95% conﬁdence intervals obtained in a general linear
model (ANOVA), adjusted for the use of lipid-lowering drugs and for each of the other car-
diovascular risk factors, whereby age, body mass index, LDL cholesterol, HDL cholesterol,
eGFR (CKD-EPI), and triglycerides (log transformed), were included as continuous rather
than categorial covariables.
b Compared to the ﬁrst category of each variable.
c Thresholds of 26 and 27 kg/m2 apply to males and females, respectively.
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Fig. 1. Association of MPO quartiles with markers of inﬂammation and vascular damage. MPO plasma concentrations were stratiﬁed into quartiles; values represent estimated marginal
means and 95% conﬁdence intervals obtained in a general linear model (ANOVA), adjusted for the use of lipid-lowering drugs and for each of the other factors, whereby age, body mass
index, LDL-C, HDL-C, and triglycerides (log transformed), were included as continuous rather than categorial co-variables. Signiﬁcance is indicated by *(P b 0.05), **(P b 0.01), and
***(P b 0.001) compared to the ﬁrst MPO quartile. (Interleukin-6, IL-6; C-reactive protein, CRP; serum amyloid A, SAA; vascular cellular adhesion molecule-1, VCAM-1; intercellular
adhesion molecule-1, ICAM-1).
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92 (3.1%) of cancer, and 96 (3.2%) died of other causes. HRs for death
from cardiovascular causes according to MPO levels were slightly
higher compared to those obtained for mortality from all causes in the
entire study population and in the CAD subgroup, respectively
(Table 5 [Models 1–3], Fig. 2). In the highest MPO quartile unadjustedTable 3A
The association of MPO polymorphisms with plasma MPO concentrations (dominant model).
Sequence variation Position Patients (n) MPOa (n
c.−822CNA (rs2243827) Non-coding
CC 2135 32.9 (31
CA or AA 901 37.2 (35
c.−765TNC (rs2243828) Non-coding
TT 1914 32.9 (31
TC or CC 1122 36.2 (34
c.-653GNA (rs2333227) Non-coding
GG 1942 33.0 (31
GA or AA 1094 36.2 (34
g.287CNT (rs2856857) Non-coding
CC 2134 32.9 (31
CT or TT 902 37.2 (35
g.5237GNA (rs11575868) Non-coding
GG 2593 34.3 (33
GA or AA 442 32.7 (30
g.9890ANC (rs2071409) Non-coding
AA 2161 34.2 (33
AC or CC 875 33.8 (31
c.157GNT (rs7208693) Val53Phe
GG 2596 34.3 (33
GT or TT 456 32.8 (30
c.2149TNC (rs2759) Ile717Val
TT 2855 33.8 (32
TC or CC 181 40.1 (35
a Means and 95% conﬁdence intervals.
b Compared to the ﬁrst category of each variable.(Model 1) and fully adjusted HRs (Model 3) for the entire study
population were 1.90 (95% CI: 1.45–2.48, P b 0.001) and 1.42 (95% CI:
1.07–1.88, P= 0.010), respectively. For CAD patients HRs in the fourth
MPO quartile were 1.86 (1.40–2.45, P b 0.001, unadjusted model) or
1.48 (1.10–1.98, P= 0.009, fully adjusted model) (Table 5). In patients
without CAD (n= 645, 43 cardiovascular deaths), MPO levels were notg/mL) Differenceb (%) P Minor allele frequency
.7–34.1)
.2–39.4) +13.3 b0.00 0.16
.7–34.2)
.3–38.1) +10.0 0.004 0.21
.7–34.4)
.4–38.1) +10.0 0.004 0.20
.7–34.1)
.2–39.4) +13.3 b0.001 0.16
.2–35.5)
.1–35.4) −4.8 0.276 0.08
.0–35.5)
.9–35.8) −1.1 0.761 0.16
.2–35.5)
.8–35.6) −4.6 0.301 0.08
.7–34.8)
.3–45.6) +18.9 0.009 0.03
Table 3B
The association of MPO polymorphisms with plasma MPO concentrations (co-dominant model).
Sequence variation Position Patients (n) MPOa (ng/mL) Difference b (%) P Minor allele frequency
c.−822CNA (rs2243827) Non-coding
CC 2135 32.9 (37.7–34.1)
CA 813 37.3 (35.1–39.6) +13.5 b0.001
AA 88 36.6 (30.5–43.9) +11.4 0.255 0.16
c.−765TNC (rs2243828) Non-coding
TT 1914 32.9 (31.7–34.2)
TC 986 36.2 (34.2–38.2) +9.9 0.006
CC 136 36.5 (31.5–42.2) +10.9 0.183 0.21
c.−653GNA (rs2333227) Non-coding
GG 1942 33.0 (31.7–34.4)
GA 962 36.2 (34.2–38.2) +10.0 0.007
AA 132 36.7 (31.6–42.6) +11.3 0.171 0.20
c.287CNT (rs2856857) Non-coding
CC 2134 32.9 (31.7–34.1)
CT 814 37.3 (35.1–39.6) +13.4 b0.001
TT 88 36.6 (30.5–43.9) +11.4 0.255 0.16
g.5237GNA (rs11575868) Non-coding
GG 2593 34.3 (33.2–35.5)
GA 427 32.5 (29.9–35.3) −5.3 0.235
AA 16 37.6 (24.5–57.7) +9.6 0.675 0.08
g.9890ANC (rs2071409) Non-coding
AA 2161 34.2 (33.0–35.5)
AC 796 33.7 (31.8–35.8) −1.4 0.708
CC 79 34.8 (28.7–42.2) +1.9 0.852 0.16
c.157GNT (rs7208693) Val53Phe
GG 2596 34.3 (33.2–35.5)
GT 424 32.4 (29.8–35.2) −5.5 0.212
TT 16 43.3 (38.2–66.4) +26.1 0.289 0.08
c.2149TNC (rs2759) Ile717Val
TT 2855 33.8 (32.7–34.8)
TC 178 40.0 (35.2–45.4) +18.4 0.012
CC 3 51.4 (19.2–137.7) +52.2 0.401 0.03
a Means and 95% conﬁdence intervals.
b Compared to the ﬁrst category of each variable.
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1–3]). Comparable results were obtained in a subgroup of patients
with CAD deﬁned≥50% of stenosis (Supplementary Table IIIB). Statisti-
cal analysis in the subgroup of individuals without CAD or with stable
CAD (n = 2068, 311 cardiovascular deaths) revealed higher HRs
compared to the entire study population (Supplementary Table IIIB).
Both, HRs for total and cardiovascular mortality were only slightly
attenuated by additional adjustment for TnT (Supplementary Table IV).Table 4
Hazard ratios for death from all causes according to MPO concentrations.
MPO (ng/mL) Deaths n (%) Model 1 OR (95% CI) P
All individuals (n = 3036)
1st quartile (b21) 136 (18) 1.0reference
2nd quartile (21–30) 170 (23) 1.28 (1.02–1.60) 0.0
3rd quartile (31–45) 160 (22) 1.27 (1.01–1.60) 0.0
4th quartile (N45) 242 (30) 1.76 (1.42–2.17) b0.0
Angiographic CAD (n = 2391)
1st quartile (b21) 122 (21) 1.0reference
2nd quartile (21–30) 154 (26) 1.30 (1.03–1.65) 0.0
3rd quartile (31–45) 139 (25) 1.26 (0.99–1.60) 0.0
4th quartile (≥45) 212 (32) 1.70 (1.36–2.12) b0.0
None CAD (n = 645)
1st quartile (b21) 14 (9) 1.0reference
2nd quartile (21–30) 16 (10) 1.14 (0.56–2.33) 0.7
3rd quartile (31–45) 21 (13) 1.52 (0.77–3.00) 0.2
4th quartile (≥45) 30 (19) 2.21 (1.18–4.18) 0.0
Model 1: unadjusted.
Model 2: adjusted for age and gender.
Model 3: in addition adjusted for coronary artery disease (none, stable CAD, unstable CAD,NSTEM
smoking status, eGFR (CKD-EPI), LDL-C, HDL-C, and triglycerides.3.7. MPO, HDL and mortality
Next, a possible effect of MPO levels on the association of HDL-C and
mortality was investigated. In the subgroup with low MPO levels,
increasing concentrations of HDL-C were signiﬁcantly associated with
reduced risk for mortality (Supplementary Table V). In the subgroup
with highMPO levels, the association of HDL-Cwith total and cardiovas-
cular mortality was attenuated indicating a weaker protective effect ofModel 2 OR (95% CI) P Model 3 OR (95% CI) P
1.0reference 1.0reference
33 1.26 (1.00–1.58) 0.046 1.18 (0.93–1.49) 0.178
38 1.20 (0.96–1.51) 0.113 1.08 (0.85–1.37) 0.547
01 1.60 (1.30–1.97) b0.001 1.34 (1.09–1.67) 0.009
1.0reference 1.0reference
30 1.28 (1.01–1.62) 0.042 1.21 (0.95–1.56) 0.121
65 1.19 (0.93–1.51) 0.172 1.14 (0.83–139) 0.576
01 1.58 (1.26–1.97) b0.001 1.48 (1.08–1.72) 0.009
1.0reference 1.0reference
23 1.12 (0.55–2.29) 0.764 1.18 (0.57–2.47) 0.660
23 1.45 (0.74–286) 0.279 1.37 (0.67–2.79) 0.388
14 1.88 (0.97–3.56) 0.051 1.66 (0.84–3.28) 0.143
I, STEMI), the use of lipid-loweringdrugs, bodymass index, type 2 diabetes, hypertension,
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Fig. 2. Cumulated survival functions for all cause and cardiovascular mortality. Cumulated survival functions for total (top panels) and cardiovascularmortality (bottompanels) according
to quartiles (Q1–Q4) ofMPO in all individuals (left panels) or in patients with angiographic CAD (right panels). Curveswere estimated using a proportional hazardmodel adjusted for age,
gender and cardiovascular risk factors. For HRs and conﬁdence intervals, see Tables 4 and 5 (Model 3).
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tion ofMPO andHDL-C revealed that the interactionwas not signiﬁcant.
Similar results were obtainedwhen quartiles of apolipoprotein A-I were
analysed in the two subgroups (Supplementary Table V).Table 5
Hazard ratios for death from cardiovascular causes according to MPO concentrations.
MPO (ng/mL) Deaths n (%) Model 1 OR (95% CI) P
All individuals (n = 3013)
1st quartile (b21) 82 (11) 1.0reference
2nd quartile (21–30) 108 (13) 1.35 (1.01–1.80) 0.0
3rd quartile (31–45) 94 (14) 1.24 (0.93–1.67) 0.1
4th quartile (N45) 158 (18) 1.90 (1.45–2.48) b0.0
Angiographic CAD (n = 2368)
1st quartile (b21) 75 (13) 1.0reference
2nd quartile (21–30) 98 (16) 1.35 (1.00–1.82) 0.0
3rd quartile (31–45) 83 (14) 1.23 (0.90–1.67) 0.2
4th quartile (≥45) 143 (20) 1.86 (1.40–2.45) b0.0
None CAD (n = 645)
1st quartile (b21) 7 (4) 1.0reference
2nd quartile (21–30) 10 (6) 1.42 (0.54–3.72) 0.4
3rd quartile (31–45) 11 (7) 1.59 (0.62–4.10) 0.3
4th quartile (≥45) 15 (9) 2.19 (0.89–5.37) 0.0
Model 1: unadjusted.
Model 2: adjusted for age and gender.
Model 3: in addition adjusted for coronary artery disease (none, stable CAD, unstable CAD,NSTEM
smoking status, eGFR (CKD-EPI), LDL-C, HDL-C, and triglycerides.3.8. Reclassiﬁcation analysis
We used ROC and reclassiﬁcation analyses to assess the predictive
value of MPO for total and cardiovascular mortality. The addition ofModel 2 OR (95% CI) P Model 3 OR (95% CI) P
1.0reference 1.0reference
43 1.33 (1.00–1.77) 0.055 1.20 (0.89–1.62) 0.237
48 1.18 (0.88–1.59) 0.276 1.03 (0.76–1.40) 0.760
01 1.73 (1.32–2.25) b0.001 1.42 (1.07–1.88) 0.010
1.0reference 1.0reference
53 1.33 (0.98–1.80) 0.066 1.23 (0.90–1.69) 0.197
03 1.16 (0.85–1.59) 0.353 1.05 (0.75–1.45) 0.688
01 1.73 (1.31–2.28) b0.001 148.(1.10–1.98) 0.009
1.0reference 1.0reference
80 1.39 (0.53–3.65) 0.504 1.30 (0.49–3.43) 0.600
38 1.51 (0.59–3.91) 0.391 1.18 (0.44–3.15) 0.742
87 1.86 (0.76–4.58) 0.176 1.47 (0.58–3.73) 0.415
I, STEMI), the use of lipid-loweringdrugs, bodymass index, type 2 diabetes, hypertension,
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(age, sex, body mass index, hypertension, HDL-C, LDL-C, triglycerides,
smoking, CAD, and diabetes mellitus) did not signiﬁcantly increase
the area under the ROC curve for total mortality (0.733 vs. 0.736) and
cardiovascular mortality (0.714 vs. 0.716, respectively, P = 0.093,
Supplementary Fig. III). However, reclassiﬁcation analysis revealed im-
provement on addition of MPO. The net reclassiﬁcation improvement
for total mortality was 9.2% (95% CI: 7.4 to 17.6, P = 0.033), the
integrated discrimination improvement was 0.0032 (95% CI: 0.0008 to
0.0057, P = 0.011). Similar results were obtained for cardiovascular
death: net reclassiﬁcation improvement was 10.1% (95% CI: 0.2 to
20.2, P = 0.049), integrated discrimination improvement was 0.0035
(95% CI: 0.0004 to 0.0065, P= 0.028).
3.9. MPO genotype and mortality
We analysed the association of the instrumental variable with total
and cardiovascular mortality using Cox proportional hazard models
with adjustment for established cardiovascular risk factors. HRs per
1 SD in the genotype category 1 was 1.01 (95% CI: 0.89–1.15, P =
0.865) compared to category 0/2 for death from all causes and 0.98
(95% CI: 0.83–1.16, P= 0.841) for death from cardiovascular causes,
respectively.
To estimate the causal effect of MPO concentrations on total and
cardiovascular mortality we calculated the causative HR based on the
HR for total and cardiovascular mortality and on the mean difference
of MPO concentration between the genotype categories. The causative
HRs per 1 SD MPO were 1.07 (95% CI: 0.18–1.95) for total mortality
and 0.86 (95% CI: 0.06–2.03) for cardiovascular mortality, respectively.
4. Discussion
This is the ﬁrst study investigating associations between various
MPO polymorphisms, MPO concentrations, and mortality in patients
who underwent coronary angiography. High levels of MPO predicted
total and cardiovascular mortality independent of established cardio-
vascular risk factors. The higher HRs for cardiovascular mortality
compared to totalmortality suggested thatMPO is involved in the path-
ogenesis of cardiovascular diseases. We calculated higher HRs for total
and cardiovascular mortality in a subgroup of patients without ACS
compared to the entire study population suggesting thatMPO is predic-
tive for long-term outcome and that inclusion of ACS patients did not
affect the association of MPO with mortality. Inclusion of MPO concen-
tration in prognostic models for total and cardiovascular mortality
slightly improved risk assessment. Finally, ﬁve out of eight MPO
polymorphisms were associated with MPO levels but no signiﬁcant
association of MPO genotype with total or cardiovascular mortality
was found.
In a prospective case–control study in apparently healthy individ-
uals, MPO predicted future risk of CAD independent of other cardiovas-
cular risk factors [21]. MPO concentrationswere found to be elevated in
patients with stable CAD [7], ACS [10,22], and acute MI [23,24]. MPO
concentrations were further associated with the severity of CAD [11]
and with complex lesion morphology on angiography [25]. Further-
more, MPO–DNA complexes were positively associated with thrombin
generation and signiﬁcantly elevated in patients with severe coronary
atherosclerosis or extremely calciﬁed coronary arteries [26]. However,
in the present study MPO levels did not differ between CAD and non-
CAD patients and levels of MPO were not associated with the severity
of CAD as determined by the Friesinger coronary score [18].
Several studies addressed the prognostic value of MPO in patients
with ACS [10,12,22,27–29]. In individuals with chest pain MPO concen-
trations at presentation of patients were predictive of major adverse
coronary events after 30 days and 6 months [10,22]. In another study
[29] the authors reported that MPO levels predicted short-term risk ofmajor adverse coronary events even in patients with normal cardiac
TnT levels.
Only a few studies investigated the association of MPO concentra-
tions with long-term risk for major adverse coronary events. MPO con-
centrations were found to be elevated one to four days after acute MI
and were predictive of mortality over a 5-year follow-up independent
of other risk markers [23]. In one study with a follow-up of 3 years
(1895 patients with stable CAD), MPO concentrations were associated
with a 1.71-fold risk for major adverse coronary events [30]. Another
group [31] failed to reveal an association of MPO levels with mortality
in 382 patients with stable CAD. Heslop and coworkers [32] were the
ﬁrst to report an association ofMPO levelswith cardiovascularmortality
(885 coronary angiography patients) with adjusted HRs slightly higher
(2.06 vs. 1.48) than observed in the present study. The percentage of
patients with severe CAD (stenosis ≥50%) was slightly higher as in
the present study (93 vs. 87%). We observed even lower HRs in a
subgroup of individuals with CAD (stenosis ≥50%). This could be due
to a longer follow-up time period in the study by Heslop and coworkers
[32] (13.5 vs. 7.5 years). However, the number of cases in the LURIC
cohort (n = 3036) was considerably higher compared to all published
studies.
Previous studies suggested a causal role of MPO in the development
of endothelial dysfunction [33] by directly promoting catalytic
consumption of nitric oxide [34,35]. We here found strong correlations
between the levels of MPO and circulating adhesionmolecules VCAM-1
and ICAM-1, which is indicative for increased endothelial activation in
subjects with high MPO levels. Furthermore, we observed associations
of MPO concentration with markers of systemic inﬂammation, i.e. IL-6,
CRP, SAA, and ﬁbrinogen, respectively. This result is in line with previ-
ous studies reporting correlations of MPO with CRP and/or ﬁbrinogen
[33,36]. The association of MPO levels with inﬂammatory markers may
be due to a reverse causation. Cytokines released from macrophages in
atherosclerotic plaques trigger the synthesis of pro-inﬂammatory
proteins and may favour recruitment and activation of MPO-containing
leukocytes.
To elucidate a potential causal relationship between MPO and mor-
tality, a Mendelian randomization approach was applied. We identiﬁed
a genetic instrumental variable based on two SNPs that were associated
with MPO concentrations. The genetic variable was not signiﬁcantly
associated with total and cardiovascular mortality. The effects of the
genetic variable on HRs for both endpoints were weaker than predicted
from the associations of the genetic variable with MPO levels and the
MPO levels with mortality. Thus, the Mendelian randomization analysis
provided no evidence for a causal role of MPO in the pathogenesis of
CAD. The high concentrations of circulating MPO could be more likely
a marker of the atherosclerotic burden than the primary initiator of
atherosclerosis. However, a limitation of this analysis might be that
the instrument variable explained only a small proportion of variance
of the MPO concentration.
Lipid lowering drugs have recently been reported to down-regulate
MPO-speciﬁc oxidation products [37] as well as systemic MPO levels in
patients with ACS [38], ﬁndings that have been conﬁrmed in patients
undergoing coronary angiography (Table 2). Natural or synthetic statins
strongly suppress MPO on mRNA level [39]. These authors [39]
suggested that the suppression is mediated by a promoter element
which encodes for the−463G/A (c.−653GNA according to the current
manuscript) polymorphismupstreamof humanMPO. This is in linewith
our ﬁnding that statin treatment lowers plasma MPO concentrations.
Several studies addressed the association of MPO polymorphisms, in
particular−463G/A, withMPO levels [40–44]. In apparently healthy in-
dividuals, the A allele did not alterMPO concentrations [40]. However, it
seemed to protect from symptomatic and angiographically proven CAD
[41,45]. Two studies reported that the A allele was associated with a
lower risk for cardiovascular events [42,45]. In all studies addressing
the relationship between−463G/A MPO polymorphism, MPO levels
and cardiovascular events, the low number of patients participating is
104 H. Scharnagl et al. / International Journal of Cardiology 174 (2014) 96–105a limiting factor. This is the ﬁrst report studying 8 different MPO
polymorphisms (so far only followed in a cohort of 638 individuals
from the Quebec Family study [20]) in a group of patients with different
risks for cardiovascular disease and/or atherosclerosis including CAD.
We demonstrate that the minor allele of ﬁve MPO polymorphisms
(four polymorphisms are located in the non-coding region) increases
plasma MPO levels, but has no effect on the prevalence of CAD as well
as on total and cardiovascular mortality.
Recent progress in the therapeutic management has improved the
survival rates of patients with acute coronary syndromes, once they
reach in-hospital acute care units [46,47]. Therefore, the prevalence of
patients with chronic CAD will increase in the future. While risk scores
(e.g. TIMI and GRACE) for predicting short- and mid-term prognosis
have been suggested, few such instruments exist for assessing long
term prognosis [48,49], which is commonly considered only in yet
asymptomatic persons [50,51]. The examination of novel biomarkers
associated with long-term prognosis of patients referred to coronary
angiography — as conducted in the current study — may contribute to
close this diagnostic gap.
4.1. Limitations
Several limitations of the present study warrant consideration. (i)
The participants are at intermediate or high cardiovascular risk and
our results might not be applicable to patients at low risk. (ii) The
study population consisted of selectively enrolled middle-aged to
elderly Caucasians; therefore the results cannot be generalized to youn-
ger individuals or other races or ethnicities. (iii) As coronary angiogra-
phy was indicated in each study participant a referral bias may occur.
The deﬁnition of the coronary artery status, however, is at the same
time the strength of the present study. The prevalence of clinically
asymptomatic coronary atherosclerosis has been reported to be high
at 50 years of age or older [52]. Hence, angiography-based recruitment
prevents inadvertent allocation of individuals with signiﬁcant, clinically
unapparent CAD to the control group.
5. Conclusions
So far, this study is the largest to investigate the predictive value of
MPO for cardiovascular mortality. The results obtained from the genetic
analysis of theMPO locus do not support a causal role of MPO in the de-
velopment of cardiovascular disease. The observed association of MPO
concentration with total and cardiovascular mortality is therefore likely
due to reverse causation. Yet, the determination of the MPO concentra-
tion may be a useful adjunct to the assessment of the risk of future car-
diovascular events.
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